Skip to main content
Addgene

(318) pcDNA3.1-myc-OGA(1-400)D174N
(Plasmid #168096)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 168096 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pcDNA3.1(+)
  • Backbone manufacturer
    Invitrogen
  • Backbone size w/o insert (bp) 5350
  • Total vector size (bp) 6592
  • Vector type
    Mammalian Expression
  • Selectable markers
    Neomycin (select with G418)

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    myc-OGA(1-400, D174N)
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    1242
  • Mutation
    D174N catalytically inactive OGA
  • Promoter T7/CMV
  • Tag / Fusion Protein
    • myc (N terminal on insert)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site Sgfl (not destroyed)
  • 3′ cloning site XbaI (not destroyed)
  • 5′ sequencing primer T7 fwd
  • 3′ sequencing primer BGH rev
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    (318) pcDNA3.1-myc-OGA(1-400)D174N was a gift from Christina Woo (Addgene plasmid # 168096 ; http://n2t.net/addgene:168096 ; RRID:Addgene_168096)
  • For your References section:

    Target protein deglycosylation in living cells by a nanobody-fused split O-GlcNAcase. Ge Y, Ramirez DH, Yang B, D'Souza AK, Aonbangkhen C, Wong S, Woo CM. Nat Chem Biol. 2021 Mar 8. pii: 10.1038/s41589-021-00757-y. doi: 10.1038/s41589-021-00757-y. 10.1038/s41589-021-00757-y PubMed 33686291